Therapy for AML patients in WV

Despite improved understanding of the significant heterogeneity of AML secondary to cytogenetic and molecular markers, there has not been significant improvement in therapy. We propose that understanding drug response and emergence of resistance will be enhanced if we can integrate big data across multiple phenotypic and genomic endpoints ultimately allowing for the identification of novel targets.  To this end we will i) utilize a chemical biology approach to determine patient specific vulnerabilities in pathways with respect to survival  ii) genetically profile using whole exome sequencing, RNA sequencing and chip Seq and iii) examine the pathology of the bone marrow niche as consequence of disease progression and drug treatment over time. Each of these endpoints will be measured in the same patient specimens. The key to the success of this project will be a highly multi-disciplinary team that includes bioinformaticians, computational system biologists, molecular biologist, pharmacologist, pathologist and medical oncologists.  In addition this is a project that has an active collaboration with Jim Denvir at Marshall University

This project is supported by a WVU_Marshall pilot award